Pre-existing Antibody: Biotherapeutic Modality-Based Review

AAPS Journal

Volumn 18, Issue 2, 2016, Pages 311-320

  Gorovits, Boris ^a   Clements Egan, Adrienne ^b   Birchler, Mary ^c   Liang, Meina ^d   Myler, Heather ^e   Peng, Kun ^f   Purushothama, Shobha ^g   Rajadhyaksha, Manoj ^h   Salazar Fontana, Laura ⁱ   Sung, Crystal ⁱ   Xue, Li ^a  

^a PFIZER INC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c GLAXOSMITHKLINE   (United States)

^d MEDIMMUNE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f GENENTECH INC   (United States)

^g UCB PHARMA   (Belgium)

^h REGENERON PHARMACEUTICALS INC   (United States)

ⁱ SANOFI   (France)

Author keywords

anti drug antibody; immunogenicity; pre existing antibody

Indexed keywords

ANTIBODY DRUG CONJUGATE; CYTOKINE; DRUG ANTIBODY; EPITOPE; GROWTH FACTOR; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN; IMMUNOTOXIN; MACROGOL; MONOCLONAL ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL PRODUCT;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL THERAPY; CHEMICAL MODIFICATION; CROSS REACTION; DRUG ANTIBODY ASSAY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; ENZYME REPLACEMENT; GENE THERAPY; IMMUNOASSAY; IMMUNOGENICITY; PEGYLATION; ANIMAL; BLOOD; HUMAN; IMMUNOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; HUMANS;

EID: 84959527132     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-9878-1     Document Type: Article

References (99)

1. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today. 1998;19(5):209–11.
2. Sauerborn M, Schellekens H. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins? Curr Opin Biotechnol. 2009;20(6):715–21.
3. Soos JM, Polsky RM, Keegan SP, Bugelski P, Herzyk DJ. Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species. Clin Immunol. 2003;109(2):188–96.
4. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Immunogenicity Assessment for Therapeutic Protein Products. U.S. Department of Health and Human Services Food and Drug Administration (FDA) 2013; Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
5. Ballard JL, Weaver FA, Singla NK, Chapman WC, Alexander WA. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg. 2010;210(2):199–204. doi:10.1016/j.jamcollsurg.2009.09.042.
6. Matsuo T, Suzuki S, Matsuo M, Kobayasi H. Preexisting antibodies to platelet factor 4-heparin complexes in patients with acute coronary syndrome who have no history of heparin exposure. Pathophysiol Haemost Thromb. 2005;34(1):18–22. doi:10.1159/000088543.
7. Strullu M, Corradini N, Audrain M, Orsonneau JL, Bouige D, Thomare P, et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2010;51(8):1464–72. doi:10.3109/10428194.2010.494316.
8. Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Future Oncol (London, England). 2014;10(16):2615–27. doi:10.2217/fon.14.138.
9. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109–17.
10. Liu Y, Reidler H, Pan J, Milunic D, Qin D, Chen D, et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J Pharmacol Toxicol Methods. 2011;64(3):238–45.
11. Brooks DA. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab. 1999;68(2):268–75. doi:10.1006/mgme.1999.2894.
12. Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet. 2003;361(9369):1608–13. doi:10.1016/s0140-6736(03)13311-9.
13. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology. 1998;51(6):1698–702.
14. van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies—effects on treatment and immunogenicity. mAbs. 2015;7(4):662–71. doi:10.1080/19420862.2015.1048411.
15. Sorensen PS. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Disord. 2008;1(2):62–78. doi:10.1177/1756285608095144.
16. Tillmann H, Ganson NJ, Patel K, Thompson AJ, Abdelmalek M, Moody T, et al. 307 High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J Hepatol. 2010;52:S129. doi:10.1016/S0168-8278(10)60309-1.
17. Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood. 1999;93(10):3250–8.
18. Ward BJ, Landry N, Trepanier S, Mercier G, Dargis M, Couture M, et al. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine. 2014;32(46):6098–106. doi:10.1016/j.vaccine.2014.08.079.
19. Xue L, Fiscella M, Rajadhyaksha M, Goyal J, Holland C, Gorovits B, et al. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. AAPS J. 2013;15(3):852–5.
20. Gorovits B, McNally J, Fiorotti C, Leung S. Protein-based matrix interferences in ligand-binding assays. Bioanalysis. 2014;6(8):1131–40. doi:10.4155/bio.14.56.
21. Chen K, Page JG, Schwartz AM, Lee TN, DeWall SL, Sikkema DJ, et al. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. J Immunol Methods. 2013;394(1–2):22–31. doi:10.1016/j.jim.2013.04.011.
22. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658–73. doi:10.1208/s12248-014-9599-2.
23. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999;45(7):942-56.
24. Bjerner J, Olsen KH, Bormer OP, Nustad K. Human heterophilic antibodies display specificity for murine IgG subclasses. Clin Biochem. 2005;38(5):465–72.
25. Tatarewicz S, Miller JM, Swanson SJ, Moxness MS.Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics J Immunol Methods. 2010;357(1-2):10-6. doi:10.1016/j.jim.2010.03.012.
26. Bautista AC, Wullner D, Moxness M, Swanson SJ, Chirmule N, Jawa V. Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis. 2010;2(4):721–31. doi:10.4155/bio.10.24.
27. Carrasco-Triguero M, Mahood C, Milojic-Blair M, Amaya C, Ruppel J, Hong K, et al. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. Bioanalysis. 2012;4(16):2013–26.
28. Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J Pharm Biomed Anal. 2011;55(5):1041-9. doi:10.1016/j.jpba.2011.03.008.
29. O'Hara DM, Theobald V, Egan AC, Usansky J, Krishna M, TerWee J, et al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J. 2012;14(2):316–28. doi:10.1208/s12248-012-9334-9.
30. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267–81. doi:10.1016/j.jpba.2008.09.020.
31. Warren DJ, Bjerner J, Paus E, Bormer OP, Nustad K. Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem. 2005;51(5):830–8. doi:10.1373/clinchem.2004.046979.
32. Xue L, Johnson R, Gorovits B. Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum. AAPS J. 2010;12(1):98–106. doi:10.1208/s12248-009-9165-5.
33. Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, et al. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia: Off J World Fed Hemophilia. 2014;20(2):200–6. doi:10.1111/hae.12283.
34. Glaros EN, Turner CT, Parkinson EJ, Hopwood JJ, Brooks DA. Immune response to enzyme replacement therapy: single epitope control of antigen distribution from circulation. Mol Genet Metab. 2002;77(1-2):127–35.
35. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood. 1993;82(8):2485–93.
36. Arnold DF, Misbah SA. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(25):2735–6.
37. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28(8):863–7. doi:10.1038/nbt.1651.
38. van Ree R, Cabanes-Macheteau M, Akkerdaas J, Milazzo JP, Loutelier-Bourhis C, Rayon C, et al. Beta(1,2)-xylose and alpha(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens. J Biol Chem. 2000;275(15):11451–8.
39. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131(2):366–78. doi:10.1053/j.gastro.2006.04.030.
40. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16(8):1367–75. doi:10.1002/ibd.21179.
41. Springer GF. T and Tn, general carcinoma autoantigens. Science (New York, NY). 1984;224(4654):1198–206.
42. Thompson J, Hu H, Scharff J, Neville Jr DM. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem. 1995;270(47):28037–41.
43. Myler H, Felix T, Zhu J, Hruska M, Piccoli SP. Measuring biotherapeutics with endogenous counterparts and pre-existing antibodies: an interferon case study. Bioanalysis. 2014;6(8):1113–22.
44. Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996;6(3):109–19.
45. Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(12):1172–83. doi:10.1111/apt.12330.
46. Xue L, Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J. 2013;15(3):893–6. doi:10.1208/s12248-013-9497-z.
47. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. mAbs. 2009;1(4):332–8.
48. Tatarewicz SM, Juan G, Swanson SJ, Moxness MS. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods. 2012;382(1-2):93–100. doi:10.1016/j.jim.2012.05.009.
49. Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12(6):R221. doi:10.1186/ar3208.
50. Mandy WJ. A new serum factor in normal rabbits. 3. Specificity for antigenic determinants uncovered by papain or pepsin digestion. J Immunol. 1967;99(4):815-24
51. Brezski RJ, Knight DM, Jordan RE. The origins, specificity, and potential biological relevance of human anti-IgG hinge autoantibodies.Scientific World Journal. 2011 May 26;11:1153-67. doi:10.1100/tsw.2011.107.
52. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets.Blood. 2002;99(6):2054–9.
53. Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, Cordy JC, Lipson DA, Bayliffe AI Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33(7):1192-203. doi:10.1007/s10875-013-9915-0.
54. Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, Mahipal A. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887-95. doi:10.1007/s00280-015-2712-0.
55. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Disposition: Biol Fate Chem. 2007;35(1):9–16. doi:10.1124/dmd.106.012419.
56. Bell EA, Wall GC. Pediatric constipation therapy using guidelines and polyethylene glycol 3350. Ann Pharmacother. 2004;38(4):686–93. doi:10.1345/aph.1D297.
57. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharm Sci. 2000;3(1):125–36.
58. Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009;14(2):363–80. doi:10.1517/14728210902907847.
59. Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28 Suppl 1:15–23. doi:10.1007/s40259-013-0064-z.
60. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74(1):36–9.
61. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9(11):1319–23. doi:10.1517/17425247.2012.720969.
62. Myler H, Hruska MW, Srinivasan S, Cooney E, Kong G, Dodge R, et al. Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-lambda-1a and PEG-IFN-alpha2a in naive patients. Bioanalysis. 2015;7(9):1093–106.
63. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60. doi:10.1186/ar4497.
64. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16(2):R63. doi:10.1186/ar4500.
65. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103–11. doi:10.1002/cncr.22739.
66. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol. 2012;52(6):798–808. doi:10.1177/0091270011407068.
67. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154–69.
68. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306–11. doi:10.1097/BOR.0b013e3283521c4e.
69. Maiese WM, Lechevalier MP, Lechevalier HA, Korshalla J, Kuck N, Fantini A, et al. Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J Antibiot. 1989;42(4):558–63.
70. Wensel DL, Awwad M. Elimination of interference in immunoassays caused by anti-carbohydrate antibodies. USA: Wyeth, John, and Brother Ltd; 2008. p. 60.
71. Carrasco-Triguero M, Yi JH, Dere R, Qiu ZJ, Lei C, Li Y, et al. Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis. 2013;5(9):1007–23. doi:10.4155/bio.13.64.
72. U.S. Food and Drug Administration F. Kadcyla Prescribing Information. Ado-Trastuzumab Emtansine. Drugs @ FDA: FDA; 2013; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf.
73. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009;100(8):1359–65.
74. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006;33(1 Suppl 3):S11–6.
75. Matar AJ, Pathiraja V, Wang Z, Duran-Struuck R, Gusha A, Crepeau R, et al. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment. Transpl Immunol. 2012;27(1):52–4.
76. Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets. 2009;10(2):104–9.
77. Watanabe M, Uchida K, Nakagaki K, Trapnell BC, Nakata K. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev. 2010;21(4):263–73.
78. Suzuki H, Akama T, Okane M, Kono I, Matsui Y, Yamane K, et al. Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum. 1989;32(12):1528–38.
79. Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis. 2010;10(12):875–85.
80. Cousens LP, Mingozzi F, van der Marel S, Su Y, Garman R, Ferreira V, et al. Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother. 2012;8(10):1459–64. doi:10.4161/hv.21405.
81. Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet. 2007;81(5):1042–9. doi:10.1086/522236.
82. Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med: Off J Am Coll Med Genet. 2012;14(1):135–42. doi:10.1038/gim.2011.4.
83. Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90(2):157–63. doi:10.1016/j.ymgme.2006.09.003.
84. Hollak CE, Linthorst GE. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Mol Genet Metab. 2009;96(1):1–3. doi:10.1016/j.ymgme.2008.10.013.
85. Cugno M, Gualtierotti R, Tedeschi A, Meroni PL. Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy. Autoimmun Rev. 2014;13(1):40–8. doi:10.1016/j.autrev.2013.08.001.
86. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.[Erratum appears in Nat Med. 2006 May;12(5):592 Note: Rasko, John [corrected to Rasko, John JE]; Rustagi, Pradip K [added]]. Nat Med. 2006;12(3):342–7.
87. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther: J Am Soc Gene Ther. 2011;19(2):326–34.
88. Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011;124(16):1765–73.
89. Annoni A, Cantore A, Della Valle P, Goudy K, Akbarpour M, Russo F, et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med. 2013;5(11):1684–97.
90. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Part B Methods. 2013;24(2):59–67.
91. Orlova NA, Kovnir SV, Vorobiev II, Gabibov AG. Coagulation factor IX for hemophilia B therapy. Acta Nat. 2012;4(2):62–73.
92. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381–90.
93. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59(3):406–11.
94. Parks WP, Boucher DW, Melnick JL, Taber LH, Yow MD. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect Immun. 1970;2(6):716–22.
95. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst. 1968;40(2):319–27.
96. Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22(11):1389–401.
97. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15(3):171–81.
98. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372(9653):1894–905.
99. Liu Q, Huang W, Zhang H, Wang Y, Zhao J, Song A, et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther. 2014;21(8):732–8. doi:10.1038/gt.2014.47.